IBB241129P158000
- 0.00
- 0.000.00%
iShares Biotechnology ETF Newsroom
How to adjust the new national medical insurance catalog? Here is the explanation.
1. The success rate is 76%, with an average decline of 63%. This year, the success rate and decline of negotiating/bidding pharmaceuticals are basically equivalent to previous years; 2. This year, the fund calculation will pay more attention to the impact on fund expenditure, while also enhancing the comprehensiveness and scientific nature of the calculation work; 3. This year's catalog adjustment places more emphasis on the actual clinical needs and patients' actual medication, highlighting support for true innovation.
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330
Amgen Analyst Ratings
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Ahead of Crucial Inflation Data
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Amgen weight loss drugs have a remarkable effect of reducing 20% body weight, but with relatively high side effects, leading to a temporary large drop of over 12% during trading hours.
Although the weight loss effect of amgen's MariTide drug met expectations, the high side effects, lower than eli lilly and co's Zepbound, and the trial results falling below Wall Street's high expectations, led to amgen's stock price plunging over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk a/s, which benefited from the Biden policy rise at the same time. In a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with about 11% of patients dropping out of the trial due to side effects, higher than eli lilly's 7%.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Regeneron Pharmaceuticals Unusual Options Activity
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Amgen Decline on MariTide Data Could Be Due to Lack of More Details
BioNTech Analyst Ratings
Sector Update: Health Care Stocks Mixed Premarket Tuesday
4 Stocks to Watch on Tuesday: AMGN, BBY and More
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday Ahead of FOMC Meeting Minutes
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau
Amgen's weight loss drug can reduce weight by 20% in one year, but Wall Street is still not satisfied, causing a sharp drop in stock prices.
① The experimental obesity treatment drug MariTide from the usa pharmaceutical company amgen can help obese patients lose an average of up to 20% of their weight after one year of use, but the stock price plummeted due to data falling short of Wall Street expectations. ② Amgen claims that MariTide can lead to faster weight loss, maintain weight, and require fewer injections, but analysts question its potential side effects on bone density.
Amgen Shares Are Trading Lower Following the Results of Its Phase 2 Study With MariTide in Obesity.
Amgen Announced Data At 52 Weeks In Phase 2 Study With MariTide (Maridebart Cafraglutide, Formerly AMG 133) Subcutaneously Administered Monthly Or Less Frequently, Showing Up To ~20% Average Weight Loss At Week 52 Without A Weight Loss Plateau